Home > Insider Trading > Filing (0001209191-23-004341)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1783183	Phathom Pharmaceuticals Inc.	PHAT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1690298	Terrie Curran	C/O Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park NJ 07932	President And Chief Executive	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-01-19	97,500	$0.00	182,628	No	4	A	Direct
Common Stock	Disposition	2023-01-20	5,821	$8.20	176,807	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2023-01-19	162,500	$0.00	162,500	$8.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
162,500		2033-01-18	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,236	Indirect	by 401(k)

Footnotes

Represents restricted stock units ("RSUs") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Includes 1,408 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023.
Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.